Biotech Acquisition Company Warrant
BIOTW
BIOTW was delisted on the 2nd of February, 2023.
20 hedge funds and large institutions have $2.08M invested in Biotech Acquisition Company Warrant in 2021 Q1 according to their latest regulatory filings, with 20 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCP
Corbin Capital Partners
New York
|
+$436K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$316K |
| 3 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
+$212K |
| 4 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$212K |
| 5 |
ACM
Atalaya Capital Management
New York
|
+$196K |
Top Sellers
BIOTW Hedge Fund Activity: Q1 2021 in Review
20 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Warrant (BIOTW) for Q1 2021, worth a combined $2.08M.
Buyers outnumbered sellers: 20 funds opened new BIOTW positions and 0 closed out — a net gain of 20 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Corbin Capital Partners, opening a new position worth an estimated $436K.
- 20 institutional investors held Biotech Acquisition Company Warrant (BIOTW) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $2.08M of Biotech Acquisition Company Warrant stock for Q1 2021.
- 20 funds opened new Biotech Acquisition Company Warrant positions in Q1 2021 and 0 closed out, a net change of +20 holders.
- The largest Biotech Acquisition Company Warrant buyer in Q1 2021 was Corbin Capital Partners, an estimated $436K added.
Based on aggregated 13F filings for Q1 2021.